Skip to main content
Premium Trial:

Request an Annual Quote

Arthur Beeman, Pamela Fulmer, Jonn Beeson, Cameron Weiffenbach, Michael McShea, Peter Larkin, Garheng Kong, Rebecca Kaufman, Salveen Kochnover, Brent Kelly

Premium
Law Firm Jones Day Adds Two IP Partners, M&A Partner to California Offices
 
Three veteran attorneys have joined the law firm Jones Day as partners in its California offices:
 
Arthur Beeman and Pamela Fulmer have joined Jones Day's San Francisco office as partners in the intellectual property practice, coming to the firm from DLA Piper. Also, Jonn Beeson has joined Jones Day's Irvine, Calif., office as a partner in the mergers and acquisitions practice, coming to the firm from Latham & Watkins.
 
Beeman focuses on intellectual property litigation and commercial disputes, with national trial experience representing clients in the medical device as well as communications, Internet, software, and semiconductor industries.
 
Fulmer concentrates primarily on patent, copyright, trademark, trade secret and other intellectual property disputes. Her clients have included biotechnology and medical devices businesses, as well as companies in e-commerce and the Internet, computer hardware and software, and consumer products. Fulmer has served on the program committee for the northern California life sciences industry group BayBio, and sits on the board of directors of the Historical Society of the Northern District of California.
 
Beeson has a dozen years of experience in corporate law, in industries that include biotech, medical devices, pharmaceuticals, as well as airlines, healthcare, semiconductors, and real estate investment trusts.
 

 
Cameron Weiffenbach Joins Miles & Stockbridge’s IP, Biotech Practices
 
Cameron Weiffenbach has joined the Baltimore office of Miles & Stockbridge, where he will work in the law firm’s intellectual property and biotechnology practices.
 
An intellectual property lawyer whose experience includes more than 30 years with the US Patent and Trademark Office, Weiffenbach will focus on patent matters related to biotechnology and the life sciences, as well as chemistry.
 
Before joining Miles & Stockbridge, Weiffenbach was counsel in the Washington, DC, office of the law firm McDermott Will & Emery, and a member of the firm’s intellectual property, media and technology department.
 
Weiffenbach held various positions over his 32 years with the USPTO. Most recently, he served as an administrative patent judge at the Board of Patent Appeals and Interferences in the fields of biotechnology and chemical patent applications. He also served as a patent examiner for chemical patent applications; a protest examiner and special program examiner in the Office of the Assistant Commissioner for patents; and as Director of the Office of Enrollment and Discipline.
 
Weiffenbach earned a JD degree from the Columbus School of Law at Catholic University, a master’s degree in chemistry from the University of Maryland and a bachelor’s degree in chemistry from the State University of New York at Buffalo.
 

 
CB Richard Ellis Taps Two Professionals for Government/Public Sector Unit
 
Michael McShea and Peter Larkin have joined the Washington, DC-based Government and Public Sector Solutions group of the commercial real estate firm CB Richard Ellis.
 
McShea and Larkin — who will both hold the title of executive vice president with CBRE — will provide strategic planning and real estate transaction and advisory services for local, municipal, state and federal government entities, as well as higher education institutions, nationwide. The two will report to Ted Carter, executive managing director of the Government and Public Sector Solutions group.
 
McShea and Larkin previously worked at the Staubach Company, a commercial real estate firm that was acquired by Jones Lang LaSalle earlier this summer.
 
McShea, a 20-plus year veteran of the industry, oversaw the restructuring of more than 1 million square feet of municipal space for the District of Columbia government, under the auspices of DC’s Financial Control Board. He also played key roles in the development of the new 700,000-square-foot city hall in Tulsa, Okla., and renegotiated 1.5 million square feet of government center leases in Florida’s state capital of Tallahassee. McShea also led teams that served state government agencies in Alabama, Florida, New York, Michigan, Pennsylvania, and North Carolina.
 
Larkin, a 23-year industry veteran, has focused on developing and implementing strategic plans for a variety of real estate assets. Among projects he has been involved in are mixed-use developments developed for George Washington University, the city of Seattle, the city of Miami, Catholic University, and the US Government Printing Office. Additional clients include the city of New York; the DC government; the states of Arizona, Colorado, Florida, Michigan, Maryland and New York; and the Smithsonian Institution.
 
In their new positions, McShea and Larkin are managing real estate for public-private partnerships San Diego, Arizona’s Maricopa County, and Richmond, Va.
 
McShea has a BSci degree in business and management from the University of Maryland, while Larkin has an MBA from the Amos Tuck School of Dartmouth College, and a bachelor’s degree in Liberal Arts from Tufts University.
 

 
Garheng Kong, Rebecca Kaufman Join UF Incubator’s Biotech Advisory Group
 
Garheng Kong, a partner with the venture capital firm Intersouth Partners in Durham, NC; and Rebecca Kaufman, a lawyer with the Intellectual Property Practice Group of the law firm King & Spalding in Atlanta, have joined the University of Florida Sid Martin Biotechnology Incubator’s Biotechnology Advisory Committee.
 
The committee recruits professionals deemed to have compatible industry, business, and technical expertise to assist the Alachua, Fla., incubator in evaluating and mentoring client companies and new applications for admission. The incubator was created to foster the growth of bioscience startup companies, and is part of UF’s tech commercialization effort.
 
Kong holds a BSci in chemical engineering and a BSci in biological sciences from Stanford University. He received an MD degree from Duke’s School of Medicine, a PhD in biomedical engineering from Duke, and an MBA degree from Duke’s Fuqua School of Business. He focuses primarily on Intersouth’s life science portfolio including full-cycle investing, sourcing, syndicating, and managing and exiting investments.
 
Kaufman received her JD degree from the University of Pittsburgh School of Law, and worked on a PhD in molecular biology at the University of Pittsburgh School of Medicine and George Washington University School of Medicine. Her practice includes US and international patent prosecution, client counseling and transactional due diligence in the life sciences area. She also handles licensing, strategic collaborations and other corporate transactions involving intellectual property.
 

 
Collins Stewart Names Senior Analyst, Senior Associate in Healthcare Research Expansion
 
Collins Stewart has appointed Salveen Kochnover as a senior analyst, and Brent Kelly as a senior associate, in an expansion of the investment bank’s US-based healthcare research sector. Kochnover and Kelly will cover a group of small to large-cap biotechnology companies, and will work from the firm’s New York City office.
 
Kochnover previously worked at Jefferies & Company, where she was a senior biotechnology analyst. Earlier, she was an analyst with Aequitas Group, a healthcare consulting firm. A chartered financial analyst chartholder, Kochover received a BSci degree in biomedical and electrical engineering from Johns Hopkins University.
 
Kelly also previously worked at Jefferies & Company as a senior research associate in biotechnology, and at Prudential Equity Group as a research associate in biotechnology. Kelly received a PhD in neuroscience from Northwestern University Medical School, and a BSci degree in biology from Indiana University.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.